

**Doncaster Place and Bassetlaw Place
Medicines Optimisation Bulletin****July 2025**

Got a spare 2 minutes? Like what you see? Want to hear more from Medicines Optimisation? We need your feedback on the new style bulletin. Use the QR code opposite or follow the link: <https://forms.office.com/e/A21uYN9Jlb>

Medicines Optimisation Team Mailbox update

*There is now a new email to contact the South Yorkshire Medicines Optimisation Team SY MOT (Sheffield/Barnsley/Rotherham/Doncaster):
syicb-sheffield.syicb.medsopt1@nhs.net*

*From 1 September 2025 this will be the only way to contact the SY MOT via email. Please update your contacts for future reference.
In the interim all emails from the previous MMADMIN and RXLINE mailboxes will be diverted, but please start to use the new one from 1st September 2025.*

Useful hyperlinks for Medicines Optimisation

To open Press control and click the link below
[IMOC Webpage](#) [MPD](#)

**Information for prescribers of multidose pre-filled
Semaglutide and Tirzepatide injections**

Semaglutide injection is used weekly and is only available as a multidose pre-filled pen, each of which contains four doses so one multidose pen will last for one month.

Tirzepatide injection is also used weekly and is licensed in both a single-use and a multidose pre-filled pen form. Tirzepatide multidose pen contains four doses so one multidose pen will last for one month.

Please ensure when prescribing these items that only ONE multidose pen is prescribed per month.

GLP-1 RA Prescribing for Patients with Type 2 Diabetes

The first line injectable GLP-1 RA for treating patients with Type 2 diabetes is **semaglutide (Ozempic)**. This is listed as green and is the first line choice on the Medicines and Product Directory. Tirzepatide (Mounjaro) is listed as Amber G.

Please note this guidance is only for the prescribing of GLP-1 RA for the treatment of type 2 diabetes – **NOT** weight loss.

[Click here](#) for all TLS status and guidance on MPD

Eclipse Live Update

Well Done Doncaster as now all practices are signed up for Eclipse Live and most practices have started to review the red and amber alerts. You can still request support with Eclipse Live by contacting the following emails:

support@prescribingservices.org or Karen.jennison@nhs.net

Electronic Shared Care Pilot

To streamline the Shared Care process, the MO team will be running a pilot for the sending and replying of Shared Care Proformas electronically via AccuMail from DBTHFT Rheumatology Department.

This will be "in place of" sending a physical proforma.

The pilot, which is supported by Doncaster LMC, will last throughout Summer 2025. If positive feedback is received, we hope to expand across other specialities and Trusts in the future.

For full information and contact details : [Click Here](#)

New documents:-

- **Metolazone (Xaqua®) for Oedema related to Kidney Disease & Congestive Heart Failure (CHF)**
Amber-G Guidance [Click Here](#)



Prescribing in pregnancy and breastfeeding

BUMPS website is a useful repository of prescribing information and can be found by clicking here:

<https://www.medicinesinpregnancy.org/>

- Senokot (sennoside or senna fruit extract, senna pods) products : Use in pregnancy and lactation is now contraindicated. Experimental data suggests genotoxic risk of several anthranoids (e.g. emodin, aloe emodin). And following administration, active metabolites of anthranoids were excreted in breast milk in small amounts.
- GLP-1 medicines for weight loss and diabetes: MHRA has issued guidance for patients covering their uses, where to obtain them, risks, contraception and pregnancy, breastfeeding, depression or suicidal thoughts, and use around the time of surgery or an operation. For further information [Click here](#)
- Topiramate safety review contraindicated in pregnancy Click Here [Click Here](#)

Formulary updates June and July 2025

The following items will be added/amended on the [MPD](#)

Formulary Section	Item	Indication	PMOC Action
7.4.5	Sildenafil citrate (new orodispersible tablet formulation)	Use in adult men with erectile dysfunction	Green non formulary
4.10.2	Varenicline & Bupropion	Smoking cessation	Not routinely to be prescribed by GPs. Prescribed routinely by the smoking cessation but if there are exceptional circumstances GPs can prescribe. Green
7.4.2	Desmopressin sublingual	nocturnal enuresis/ bed wetting in children	Green Formulary in MPD section 7.4.2 Refer to local guidance document
6.4.1	Relugolix-Estradiol-Norethisterone (Ryeqo)	uterine fibroids	AMBER on MPD in line with SCP
11.6	Latanoprost/Netarsudil (Roclanda)	Glaucoma	Amber-G 2nd line in line with NICE TA1009 prescribe by brand Roclanda
1.7.2	hydrocortisone 5 mg and cinchocaine hydrochloride 5 mg suppositories and ointment	external haemorrhoids	Prescribe by brand Uniroid-HC in primary care Green Non-formulary
4.7.2	buprenorphine patches	pain	Prescribe by Brand, Bunov and Sevodyne. Replaces Butec in Primary care Green 3rd line
4.7.2	fentanyl patches	pain	Prescribe by Brand Mezolar replaces Matrifen in Primary Care Green 3rd line
2.6.2	felodipine 2.5mg 5mg and 10mg MR tablets	hypertension	Prescribe by brand Delofine in primary care Green non-formulary

DIBS Update

- Reminder: Sodium Valproate review process supporting documents are available on the IMOC website and MPD For more information [Click Here](#)

For the latest Out of Stock information Refer to your regular emails from medicines management Admin emails.

Contact us : South Yorkshire Integrated Care Board Doncaster Place Medicines Optimisation Team

Phone: 03000 213394

E-mail: syicb-sheffield.syicb.medsopt1@nhs.net